Frontlight ResearchEarly access
CompletedPhase 3
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
Key facts
- Who runs it
- Pfizer
- Where
- Birmingham, Chesterfield, Chicago, Columbus, Doral, Fort Lauderdale, Houston, Huntsville, Los Angeles, Memphis, Mesquite, Miami, Mobile, New Orleans, New York, Peoria, Philadelphia, San Antonio, Silver Spring, Stockbridge, Sugar Land, Troy, Walnut Creek, and Warren Township, United StatesSee the 25 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 526 people enrolled
- Started
- 4 Apr 2025
- Ended
- 30 Sept 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
- HZ/su VACCINE
- Record updated
- 6 November 2025
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Male and female participants 50 years of age and older who are healthy or with stable chronic medical conditions
Who cannot take part
- Prior history of any subtype of Guillain Barré syndrome of any etiology
- Previous vaccination with any licensed or investigational RSV vaccine at any time prior to enrollment, or planned receipt of a nonstudy RSV vaccine during study participation
- Previous vaccination with any licensed recombinant adjuvant zoster vaccine (Shingrix) at any time prior to enrollment, or planned receipt of a nonstudy licensed VZV vaccine (Shingrix) during study participation
- History of previous vaccination with live HZ vaccine (Zostavax) in the last 2 years from enrollment, or planned receipt through study participation
- Previous vaccination with any investigational VZV vaccine at any time prior to enrollment, or planned receipt of a nonstudy investigational VZV vaccine during study participation
- Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic corticosteroids (defined as ≥20 mg/day of prednisone or equivalent for ≥14 days), eg, for cancer or an autoimmune disease, or radiotherapy, from 60 days before study intervention administration, or planned receipt throughout the study
- Current clinically suspected or polymerase chain reaction (PCR)-confirmed ongoing episode of HZ and/or history of clinically suspected or PCR-confirmed HZ within the past 12 months
- Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination, and medication list
Where in United States
Also in 1 other country, 1 site
- Central Research AssociatesBirmingham, United States
- Clinical Research ProfessionalsChesterfield, United States
- Synexus Clinical Research US, IncChicago, United States
- Centricity Research Columbus Georgia MultispecialtyColumbus, United States
- Centricity Research Columbus Ohio MultispecialtyColumbus, United States
- Alliance for Multispecialty Research, LLCDoral, United States
- Proactive Clinical Research,LLCFort Lauderdale, United States
- DM Clinical Research - BellaireHouston, United States
- Medical Affiliated Research CenterHuntsville, United States
- Kaiser PermanenteLos Angeles, United States
- Clinical Neuroscience Solutions, Inc.Memphis, United States
- SMS Clinical ResearchMesquite, United States
- De La Cruz Research Center, LLCMiami, United States
- AMR ClinicalMobile, United States
- Delricht ResearchNew Orleans, United States
- NYU Langone HealthNew York, United States
- Optimal ResearchPeoria, United States
- DM Clinical Research - PhiladelphiaPhiladelphia, United States
- IMA Clinical Research San AntonioSan Antonio, United States
- Jadestone Clinical ResearchSilver Spring, United States
- Clinical Research AtlantaStockbridge, United States
- DM Clinical Research, Sugar LandSugar Land, United States
- Oakland Medical ResearchTroy, United States
- Diablo Clinical Research, Inc.Walnut Creek, United States
- IMA Clinical Research WarrenWarren Township, United States
About the trial
What the trial wants to find out
This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
The 2 groups in the trial
- Coadministration GroupOther group
* Visit 1 (Day 1): RSVpreF + HZ/su dose 1 * Visit 3 (Month 2): HZ/su dose 2
Treatment: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE and HZ/su VACCINE
- Sequential Administration GroupOther group
* Visit 1 (Day 1): HZ/su dose 1 * Visit 2 (Month 1): RSVpreF * Visit 3 (Month 2): HZ/su dose 2
Treatment: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE and HZ/su VACCINE
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A PHASE 3, MULTICENTER, PARALLEL-GROUP, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS ≥50 YEARS OF AGE
- Record updated
- 6 November 2025